HUE045866T2 - CD30XCD16A antitest kombinálása anti-PD-1-antagonista antitesttel terápiához - Google Patents
CD30XCD16A antitest kombinálása anti-PD-1-antagonista antitesttel terápiáhozInfo
- Publication number
- HUE045866T2 HUE045866T2 HUE16723968A HUE16723968A HUE045866T2 HU E045866 T2 HUE045866 T2 HU E045866T2 HU E16723968 A HUE16723968 A HU E16723968A HU E16723968 A HUE16723968 A HU E16723968A HU E045866 T2 HUE045866 T2 HU E045866T2
- Authority
- HU
- Hungary
- Prior art keywords
- antibody
- cd30xcd16a
- therapy
- combination
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166303.6A EP3091031A1 (en) | 2015-05-04 | 2015-05-04 | Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor |
| EP16152650 | 2016-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE045866T2 true HUE045866T2 (hu) | 2020-01-28 |
Family
ID=56026814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16723968A HUE045866T2 (hu) | 2015-05-04 | 2016-05-04 | CD30XCD16A antitest kombinálása anti-PD-1-antagonista antitesttel terápiához |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11167029B2 (https=) |
| EP (1) | EP3292153B1 (https=) |
| JP (1) | JP6609784B2 (https=) |
| CN (1) | CN107847587B (https=) |
| AU (1) | AU2016257334B2 (https=) |
| BR (1) | BR112017023579A2 (https=) |
| CA (2) | CA3219372A1 (https=) |
| CY (1) | CY1122283T1 (https=) |
| DK (1) | DK3292153T3 (https=) |
| ES (1) | ES2754557T3 (https=) |
| HR (1) | HRP20191933T1 (https=) |
| HU (1) | HUE045866T2 (https=) |
| LT (1) | LT3292153T (https=) |
| PL (1) | PL3292153T3 (https=) |
| PT (1) | PT3292153T (https=) |
| RS (1) | RS59489B1 (https=) |
| RU (1) | RU2761352C2 (https=) |
| SI (1) | SI3292153T1 (https=) |
| SM (1) | SMT201900598T1 (https=) |
| WO (1) | WO2016177846A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018226526B2 (en) | 2017-02-28 | 2025-03-13 | Affimed Gmbh | Combination of an anti-CD16A antibody with a cytokine |
| WO2018158349A1 (en) | 2017-02-28 | 2018-09-07 | Affimed Gmbh | Tandem diabody for cd16a-directed nk-cell engagement |
| CN109706164A (zh) * | 2017-10-26 | 2019-05-03 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接人和猴cd20与效应细胞抗原的桥接分子及其应用 |
| CN109706163A (zh) * | 2017-10-26 | 2019-05-03 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用 |
| BR112020018492A2 (pt) | 2018-03-14 | 2020-12-29 | Affimed Gmbh | Proteína de ligação ao antígeno egfr/cd16 biespecífica |
| CA3095373A1 (en) * | 2018-04-13 | 2019-10-17 | Affimed Gmbh | Nk cell engaging antibody fusion constructs |
| HRP20240821T1 (hr) * | 2018-08-27 | 2024-09-27 | Affimed Gmbh | Stanice nk čuvane zamrzavanjem, koje su prethodno ubačene uz protutijelni konstrukt |
| CN109402168A (zh) * | 2018-10-30 | 2019-03-01 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用 |
| JP2022536684A (ja) * | 2019-06-11 | 2022-08-18 | マイエロイド・セラピューティクス，インコーポレーテッド | マクロファージ特異的エンゲージャー組成物およびその使用方法 |
| AU2020414409A1 (en) * | 2019-12-27 | 2022-06-16 | Affimed Gmbh | Method for the production of bispecific FcyRIIl x CD30 antibody construct |
| JP2024503933A (ja) * | 2021-01-27 | 2024-01-29 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | Ｃｄ１６ａに対する単一ドメイン抗体およびその使用 |
| WO2023274183A1 (zh) | 2021-06-29 | 2023-01-05 | 江苏先声药业有限公司 | Cd16抗体及其应用 |
| EP4413039A1 (en) | 2021-10-08 | 2024-08-14 | Genmab A/S | Antibodies binding to cd30 and cd3 |
| CN118613271A (zh) * | 2021-11-04 | 2024-09-06 | 埃迪瓦生物治疗公司 | 用nk细胞和多特异性接合子治疗癌症 |
| WO2023080895A1 (en) * | 2021-11-04 | 2023-05-11 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and multispecific engagers |
| CN116059348A (zh) * | 2022-09-16 | 2023-05-05 | 四川大学华西医院 | 基于nkg2d的细胞接合器分子在清除衰老细胞中的应用 |
| WO2024114676A1 (zh) | 2022-11-29 | 2024-06-06 | 江苏恒瑞医药股份有限公司 | Cldn18.2/4-1bb结合蛋白及其医药用途 |
| AR132290A1 (es) | 2023-04-05 | 2025-06-11 | Genmab As | Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3 |
| CN117442721B (zh) * | 2023-12-20 | 2024-03-15 | 苏州艾凯利元生物科技有限公司 | 一种包括nk细胞和nk细胞接合器分子的组合物 |
| CN118791616A (zh) * | 2024-09-14 | 2024-10-18 | 苏州为度生物技术有限公司天津分公司 | 一种抗人cd16工程抗体及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| CA2611861C (en) * | 2005-06-08 | 2017-11-28 | The Brigham And Women's Hospital, Inc. | Methods and compositions for the treatment of persistent infections |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP3183269A2 (en) * | 2014-08-22 | 2017-06-28 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
-
2016
- 2016-05-04 LT LT16723968T patent/LT3292153T/lt unknown
- 2016-05-04 PT PT167239680T patent/PT3292153T/pt unknown
- 2016-05-04 JP JP2017557405A patent/JP6609784B2/ja active Active
- 2016-05-04 WO PCT/EP2016/060113 patent/WO2016177846A1/en not_active Ceased
- 2016-05-04 BR BR112017023579A patent/BR112017023579A2/pt active Search and Examination
- 2016-05-04 DK DK16723968.0T patent/DK3292153T3/da active
- 2016-05-04 RU RU2017137251A patent/RU2761352C2/ru active
- 2016-05-04 HR HRP20191933TT patent/HRP20191933T1/hr unknown
- 2016-05-04 SM SM20190598T patent/SMT201900598T1/it unknown
- 2016-05-04 RS RS20191372A patent/RS59489B1/sr unknown
- 2016-05-04 CA CA3219372A patent/CA3219372A1/en active Pending
- 2016-05-04 CN CN201680026411.5A patent/CN107847587B/zh active Active
- 2016-05-04 EP EP16723968.0A patent/EP3292153B1/en active Active
- 2016-05-04 HU HUE16723968A patent/HUE045866T2/hu unknown
- 2016-05-04 CA CA2983706A patent/CA2983706C/en active Active
- 2016-05-04 SI SI201630463T patent/SI3292153T1/sl unknown
- 2016-05-04 PL PL16723968T patent/PL3292153T3/pl unknown
- 2016-05-04 AU AU2016257334A patent/AU2016257334B2/en active Active
- 2016-05-04 ES ES16723968T patent/ES2754557T3/es active Active
-
2017
- 2017-10-19 US US15/788,177 patent/US11167029B2/en active Active
-
2019
- 2019-10-25 CY CY20191101115T patent/CY1122283T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018514576A (ja) | 2018-06-07 |
| PT3292153T (pt) | 2019-11-05 |
| CN107847587A (zh) | 2018-03-27 |
| RU2761352C2 (ru) | 2021-12-07 |
| RS59489B1 (sr) | 2019-12-31 |
| CN107847587B (zh) | 2020-10-09 |
| LT3292153T (lt) | 2019-11-11 |
| US11167029B2 (en) | 2021-11-09 |
| JP6609784B2 (ja) | 2019-11-27 |
| AU2016257334B2 (en) | 2021-08-12 |
| BR112017023579A2 (pt) | 2018-07-24 |
| CY1122283T1 (el) | 2020-11-25 |
| ES2754557T3 (es) | 2020-04-20 |
| PL3292153T3 (pl) | 2020-02-28 |
| CA2983706A1 (en) | 2016-11-10 |
| CA3219372A1 (en) | 2016-11-10 |
| WO2016177846A1 (en) | 2016-11-10 |
| AU2016257334A1 (en) | 2017-11-09 |
| SI3292153T1 (sl) | 2020-01-31 |
| EP3292153A1 (en) | 2018-03-14 |
| US20180085456A1 (en) | 2018-03-29 |
| RU2017137251A3 (https=) | 2019-10-10 |
| HK1253022A1 (zh) | 2019-06-06 |
| HRP20191933T1 (hr) | 2020-01-10 |
| DK3292153T3 (da) | 2019-10-21 |
| EP3292153B1 (en) | 2019-07-31 |
| RU2017137251A (ru) | 2019-06-04 |
| SMT201900598T1 (it) | 2020-01-14 |
| CA2983706C (en) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2025001I1 (el) | Νεα αντι-pd-l1 αντισωματα | |
| HUE045866T2 (hu) | CD30XCD16A antitest kombinálása anti-PD-1-antagonista antitesttel terápiához | |
| CL2018000370A1 (es) | Nuevos anticuerpos anti-pd-1 | |
| FR25C1022I2 (fr) | Anticorps anti-pd-1 | |
| HUE051700T2 (hu) | Anti-PD-1 antitestek | |
| EP3334824A4 (en) | PD-1 ANTIBODY | |
| BR112017001385A2 (pt) | anticorpos anti-pd-1 | |
| DK3368572T3 (da) | Anti-pd-1-antistoffer og -sammensætninger | |
| EP3387442A4 (en) | HUMANIZED ANTI-CD73 ANTIBODIES | |
| DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
| CL2016002462A1 (es) | Anticuerpos anti-ox40 y métodos de uso | |
| HUE047477T2 (hu) | Palbociclib szilárd dózisformái | |
| DK3166976T3 (da) | Anti-pd-l1-kombinationer til behandling af tumorer | |
| PL3556777T3 (pl) | Konstrukty przeciwciał wieloswoistych | |
| DK3508502T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
| IL256099A (en) | Antibody | |
| KR20180085002A (ko) | 인간화된 항-cll-1 항체 | |
| EP3383915A4 (en) | PD-1 ANTIBODY | |
| HUE061076T2 (hu) | Humanizált anti-C1s ellenanyagok alkalmazási eljárások | |
| IL260347A (en) | Therapeutic anti-cd9 antibody | |
| HRP20181572T1 (hr) | Režim doziranja spoja fgf-18 | |
| IL259101A (en) | Melflufen dosage regimens for cancer | |
| IL257368A (en) | Antibody | |
| EP3212232A4 (en) | TETRAVALENT TLR9 BISPECIFIC ANTIBODIES | |
| EP3498839A4 (en) | ANTI-PD-1 ANTIBODY |